Allergic Rhinitis Control Test questionnaire-driven stepwise strategy to improve allergic rhinitis control: a prospective study

Wang, Youna; Chen, Hao; Zhu, Rongfei; Liu, Guanghui; Huang, Nan; Li, Wenjing; Yang, Lin; Zhang, Shucheng; Qi, Shanshan; Daurès, Jean‐Pierre; Chiriac, Anca Mirela; Demoly, Pascal

doi:10.1111/all.12963

Cited by 28 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies demonstrated CD30L expression on mast cells . We previously observed significant accumulation and activation of mast cells in eosinophilic CRSwNP .…”

Section: Resultsmentioning

confidence: 49%

“…Atopic status was evaluated by a skin prick test with a panel of aeroallergens common in our area . Allergic rhinitis was diagnosed on the concordance between a typical history of allergic symptoms and the atopy test results . The diagnosis of asthma was made based on Global Initiative for Asthma guidelines .…”

Section: Methodsmentioning

confidence: 99%

“…Previous studies demonstrated CD30L expression on mast cells. 25,26 We previously observed significant accumulation and activation of mast cells in eosinophilic CRSwNP. 12,13 In this study, significant up-regulation of CD30L expression was specifically discovered in eosinophilic CRSwNP (Fig.…”

Section: Increased Accumulation Of Cd30l + Mast Cells In Eosinophilicmentioning

confidence: 97%

“…24 Allergic rhinitis was diagnosed on the concordance between a typical history of allergic symptoms and the atopy test results. 25 The diagnosis of asthma was made based on Global Initiative for Asthma guidelines. 26 Subjects who had fungal sinusitis, cystic fibrosis, an antrochoanal polyp, primary ciliary dyskinesia, systemic vasculitis, gastroesophageal reflux disease, or an acute upper respiratory tract infection within 1 month of entering the study were excluded.…”

Section: Patientsmentioning

confidence: 99%

See 3 more Smart Citations

Increased accumulation of CD30 ligand‐positive mast cells associates with eosinophilic inflammation in nasal polyps

Zhai

Zhang

et al. 2018

The Laryngoscope

View full text Add to dashboard Cite

Objective Activation of mast cells associates with eosinophilic inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP). The disease‐specific mast cell‐triggering mechanisms apart from immunoglobulin E are poorly understood in CRSwNP. CD30L/CD30 are members of the tumor necrosis factor/receptor superfamily and display immune modulatory function on mast cells. The aim of this study was to explore the expression and function of CD30 and CD30L in CRSwNP. Methods The mRNA expression of CD30 and CD30L was analyzed by real‐time polymerase chain reaction. The cellular expression of CD30L was determined by immunofluorescence staining. The soluble CD30 levels in nasal tissues were detected by enzyme‐linked immunosorbent assay. HMC‐1 cells, a human mast cell line, were cultured and stimulated with CD30. Results Compared with control tissues, CD30 mRNA expression levels were increased in eosinophilic polyps, and soluble CD30 protein levels were upregulated in both eosinophilic and noneosinophilic polyps with a greater increase in eosinophilic type. CD30 was expressed by T cells and B cells in nasal polyps. The CD30L mRNA expression levels and the number of CD30L+ cells and CD30L+tryptase+ mast cells were increased in eosinophilic polyps but not in noneosinophilic polyps as compared with control tissues. Mast cells accounted for 60% of CD30L+ cells in eosinophilic polyps. CD30 induced HMC‐1 cells to produce interleukin (IL)‐4 and IL‐13 without degranulation. Mast cells expressed IL‐4 and IL‐13 in eosinophilic polyps. The number of CD30L+tryptase+ mast cells was positively correlated with the number of eosinophils and total inflammatory cells in eosinophilic polyps. Conclusion CD30/CD30L‐mediated mast cell activation may promote the eosinophilic inflammation in CRSwNP. Level of Evidence NA Laryngoscope, 129:E110–E117, 2019

show abstract

“…Previous studies demonstrated CD30L expression on mast cells . We previously observed significant accumulation and activation of mast cells in eosinophilic CRSwNP .…”

Section: Resultsmentioning

confidence: 49%

Section: Methodsmentioning

confidence: 99%

Section: Increased Accumulation Of Cd30l + Mast Cells In Eosinophilicmentioning

confidence: 97%

Section: Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Increased accumulation of CD30 ligand‐positive mast cells associates with eosinophilic inflammation in nasal polyps

Zhai

Zhang

et al. 2018

The Laryngoscope

View full text Add to dashboard Cite

show abstract

“…In order to reach the above‐mentioned goals, a number of unsolved issues which have been partially addressed remain to be fixed and validated by the scientific community and find agreement from the other stakeholders such as regulatory agencies, pharmaceutical industry, and payers or the health technology assessment agencies (HTAs). The following—noncomprehensive—list of unsolved issues of relevance in the context of clinical trial design may give an impression of some major aspects to be addressed in the near future (NB: not all issues are relevant for all atopic conditions).…”

Section: The Unsolved Issues For the Paradigm Shiftmentioning

confidence: 99%

New opportunities and challenges in the assessment of drugs for atopic diseases

Bieber

Vieths

Broich

2016

Allergy

View full text Add to dashboard Cite

Atopic conditions (atopic dermatitis, rhinitis, and asthma) belong to the most common noncommunicable diseases and are driven by chronic inflammatory reactions. They have a strong impact on the quality of life and represent a substantial and growing socio-economic burden. Interestingly, there is an increasing interest in the development of new therapeutic options with a number of biologics and small molecules targeting potential key mechanisms in atopic conditions. However, besides the safety issue, most of the new active substances are still evaluated according to the traditional efficacy paradigm focusing on the success in treating exacerbations and flares. Instead, the future approaches in drug development and assessment should rather concentrate on the long-term control of these diseases and consider their potential as disease-modifying strategies in the era of precision medicine. To reach this goal, a number of unsolved issues have to be addressed and consensually accepted by the stakeholders in this field. Thus, a successful and rapid development of new treatments requests a paradigm shift and a new way of thinking in the mind of physicians, pharmaceutical industry, regulators, and HTAs. This seems mandatory in order to optimize drug development and to facilitate the accessibility of new therapies to the growing population of patients suffering from atopic conditions on a global level.

show abstract

Endoplasmic reticulum stress promotes local immunoglobulin E production in allergic rhinitis

Liu

Zhen

Chen

et al. 2021

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Background The role of endoplasmic reticulum (ER) stress in the pathogenesis of allergic rhinitis (AR) remains elusive. Methods Real‐time polymerase chain reaction (RT‐PCR), immunohistochemistry, and western blotting analyses were performed to detect the expression of ER stress and unfolded protein response markers: 78‐kDa glucose‐regulated protein (GRP78), C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6α), spliced X‐box binding protein 1 (sXBP‐1), and phosphorylated eukaryotic initiation factor 2α (p‐eIF2α), in inferior turbinate tissue samples from patients with AR and non‐AR controls. Nasal tissues from patients with AR were cultured ex vivo and treated with 4‐phenylbutyric acid (4‐PBA), an ER stress inhibitor. Results Compared to those in non‐AR controls, the mRNA and protein levels of GRP78, CHOP, ATF6α, sXBP‐1, and p‐eIF2α were significantly increased in nasal tissues from patients with AR. GRP78 and CHOP were mainly expressed in CD138+ plasma cells in nasal tissues from patients with AR. The frequency of IgE+CD138+ plasma cells was significantly higher in nasal tissues from patients with AR than that in non‐AR controls. IgE levels in nasal secretions and tissues were positively correlated with GRP78 and CHOP mRNA levels in the nasal tissues. After 4‐PBA treatment, the protein expression of GRP78, CHOP, ATF6α, sXBP‐1, and p‐eIF2α was significantly reduced in cultured AR‐derived nasal tissues, and IgE levels were simultaneously decreased in cultured supernatants. Conclusions ER stress may be involved in the regulation of local IgE production in patients with AR. Inhibition of ER stress potentially provides a therapeutic avenue in AR by reducing local IgE production. Level of Evidence NA

show abstract

Allergic Rhinitis Control Test questionnaire-driven stepwise strategy to improve allergic rhinitis control: a prospective study

Abstract: The majority of AR can be controlled with standard stepwise treatment. ARCT offers an objective criterion for the stepwise pharmacotherapy of AR.

Cited by 28 publications

References 26 publications

Increased accumulation of CD30 ligand‐positive mast cells associates with eosinophilic inflammation in nasal polyps

Increased accumulation of CD30 ligand‐positive mast cells associates with eosinophilic inflammation in nasal polyps

New opportunities and challenges in the assessment of drugs for atopic diseases

Endoplasmic reticulum stress promotes local immunoglobulin E production in allergic rhinitis

Contact Info

Product

Resources

About